11β-hydroxy-20α-dihydroprogesterone | 2640-53-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11β-hydroxy-20α-dihydroprogesterone
• 英文别名: (8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-((R)-1-hydroxyethyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one；(8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-[(1R)-1-hydroxyethyl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 2640-53-1
• 化学式: C₂₁H₃₂O₃
• 分子量: 332.483
• InChiKey: AIPVEEYYOOGTAW-YTOWZHFOSA-N

物化性质

• 熔点：
  228-229 °C
• 沸点：
  491.6±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  黄体酮 在 calf serum horse serum 、 Ham's F-10 medium 、 MEN medium 、 mouse adrenal Y-1 cells transformed by simian adenovirus SA-7 作用下， 反应 60.0h， 生成 (20R)-20-Hydroxy-5-pregnen-3-on 、 11β-hydroxy-20α-dihydroprogesterone
  参考文献：
  名称：

  Modification of steroidogenesis in a mouse adrenal cell line (Y-1) transformed by simian adenovirus SA-7

  摘要：

  Transformation of a steroidogenic mouse adrenal cell line (Y-1) by simian adenovirus SA7 produced a cell line with low apparent steroidogenic activity. The effect of ACTH and cholera toxin on cyclic AMP production was similar in both not transformed and virus-transformed cells and activity of cyclic AMP-dependent protein kinase was also similar in both cells. In transformed cells, cholesterol was metabolized to delta 5-3 beta-hydroxysteroids, mainly 20 alpha-dihydropregnenolone while in not transformed cells, the major metabolites were delta 4-3 ketosteroids (20 alpha-dihydro- and 11 beta-hydroxy-20 alpha-dihydroprogesterone). In both cell lines ACTH increased the metabolism of cholesterol. Further studies with labelled pregnenolone and progesterone revealed a loss of delta 5-3 beta-hydroxysteroid dehydrogenase/isomerase and 11 beta-hydroxylase activity in the transformed cells.

  DOI：

  10.1016/s0039-128x(81)90294-4

文献信息

• NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：SPHAERA PHARMA PVTD. LTD.

  公开号：US20150376225A1

  公开（公告）日：2015-12-31

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

  本发明提供了11β-羟基类固醇的新化合物、组合物及其作为药物的应用，用于预防或逆转线粒体损伤，治疗或预防与线粒体功能失调或耗竭有关的疾病，并诱导线粒体再生或重构作为治疗人或动物主体中线粒体结构和功能异常相关疾病的手段。本文还公开了诊断线粒体损伤和诊断治疗、预防或逆转线粒体损伤或耗竭的治疗剂成功或失败的方法。
• 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：Sphaera Pharma Pvt. Ltd.

  公开号：EP3309166A2

  公开（公告）日：2018-04-18

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

  本发明提供了11β-羟基类固醇的新型化合物和组合物及其作为药物的应用，用于预防或逆转对线粒体的损伤，治疗或预防与线粒体功能障碍或耗竭有关的疾病，以及诱导线粒体的再生或重组，作为治疗与人或动物体内线粒体结构和功能异常有关的疾病的一种手段。本文还公开了诊断线粒体损伤和诊断旨在治疗、预防或逆转线粒体损伤或耗竭的疗法成败的方法。